Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 10 of 13 · 376 total
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patents under grounds of anticipation and obviousness. The Board construed the key term 'filament' to require flexibility, which influenced its initial assessment of the claims. Institution was granted, setting the stage for a full trial on infringement and validity.
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
Imperative Care, Inc. v.INARI MEDICAL, INC.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.INARI MEDICAL, INC.
The PTAB instituted an IPR on Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care likely to prevail on at least one claim, based on anticipation and obviousness arguments over Schaffer, Hartley, Eller, and Garrison references.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care has successfully instituted an IPR against Inari Medical’s 11,844,921 B2 hemostasis valve patent, asserting unpatentability under §§102 and 103 based on Schaffer, Hartley, and Eller. The Board found a reasonable likelihood of success and ordered review of all challenged claims.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. successfully challenged nine claims of INARI MEDICAL's hemostasis valve patent (11697011) at the PTAB. The Board found sufficient evidence for Petitioner’s anticipation challenge against Claim 1 after adopting a broad interpretation of the term 'filament.'
Imperative Care, Inc. v.INARI MEDICAL, INC.
The Board found that the claims were unpatentable under obviousness (Grounds 3 and 4), specifically over a combination of Schaffer's valve with Hartley's string or Eller's wire. The decision hinged on finding that a POSA would have had reason to make this substitution, leading to predictable results in hemostatic device design.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom filed a joint request with the PTAB to keep their settlement agreement confidential, invoking statutory provisions for business‑confidential treatment.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have entered a confidential settlement and jointly moved to terminate IPR2024-00861 covering DexCom’s glucose‑monitor patent. The Board has not yet decided the merits, and the parties cite statutory authority for termination.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their IPR dispute over U.S. Patent 9,801,541, filing a joint motion that led the PTAB to terminate the proceeding and keep the settlement agreement confidential.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Endymed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding under 35 U.S.C. § 317.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The PTAB granted a joint motion to terminate the IPR for Jeisys Medical Inc. after the parties settled their dispute. The settlement agreement was ordered to be kept confidential, and the proceeding remains open only for EndyMed petitioners.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Jeisys Medical and Serendia have settled their dispute over U.S. Patent 9,480,836 and jointly moved to terminate the inter partes review. The Board is asked to end the proceeding before any substantive briefing or hearing.
Jeisys Medical Inc. et al. v.Serendia, LLC
Serendia and Jeisys Medical settled their IPR dispute over U.S. Patent 9,320,536, leading the PTAB to terminate the proceeding.
Jeisys Medical Inc. et al. v.Serendia, LLC
EndyMed Medical and Serendia, LLC jointly filed a request to keep their settlement agreement confidential under statutory provisions, separating it from the IPR file.
Jeisys Medical Inc. et al. v.Serendia, LLC
EndyMed Medical Ltd. and EndyMed Medical Inc. jointly moved to terminate IPR2024-00384 after reaching a settlement with patent owner Serendia, LLC. The Board was asked to end the proceeding before any oral hearing or final decision.
Jeisys Medical Inc. et al. v.Serendia, LLC
Serendia requests Director Review to terminate IPR2024-00384, arguing the Board improperly expedited institution of time‑barred petitions despite a pending ITC validity finding. The petition cites the rescinded Fintiv memo and extraordinary circumstances to seek dismissal.
Jeisys Medical Inc. et al. v.Serendia, LLC
Ilooda and Serendia have settled their dispute over a dermatology‑device patent and jointly moved to terminate Ilooda’s participation in the pending IPR, requesting the settlement remain confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
Jeisys Medical settled with SHEnB and Cartessa respondents during its IPR against Serendia, leading to a motion to suspend the schedule.
Jeisys Medical Inc. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR only for Jeisys Medical Inc. after a settlement with Serendia, while EndyMed remains as a petitioner. The settlement agreement was ordered confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
Petitioner Jeisys Medical Inc. successfully petitioned the PTAB to institute review of U.S. Patent No. 9,320,536 regarding dermatological treatment devices. The petition asserts compelling grounds for unpatentability under both 35 U.S.C. §§ 102 and 103 based on multiple prior art references.
Jeisys Medical Inc. et al. v.Serendia, LLC
Jeisys Medical Inc. and Ilooda Co., Ltd. challenged U.S. Patent No. 9,320,536 in a petition asserting anticipation (102) and obviousness (103). The challengers argue that the patent's claims are rendered unpatentable by prior art references including Mehta, Na ’848, Lee, and Livneh.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Jeisys Medical Inc.'s IPR challenge against Serendia, LLC's '836 patent was instituted by the PTAB. The Board determined that the Petitioner's grounds of obviousness over prior art like Ganz were plausible and warranted further proceedings. This decision moves the dispute toward a trial phase in the medical device technology space.
EndyMed Medical Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding. The settlement agreement is treated as confidential business information.
Avanos Medical, Inc. v.Stratus Medical, LLC
Stratus Medical’s response to Avanos’s IPR argues that the petition’s obviousness challenges fail because the alleged combination is vague, non‑enabling, and not taught by the prior art, while emphasizing commercial success and industry praise as objective indicia of non‑obviousness.
Avanos Medical, Inc. v.Stratus Medical, LLC
Petitioner Avanos Medical challenges Stratus Medical's '664 Patent, asserting that all claimed features are obvious over various combinations of prior art references in RF ablation technology. The challenge rests entirely on statutory grounds of 35 U.S.C. § 103, utilizing multiple prior art patents related to neurotomy devices.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical challenges Stratus Medical's RF neurotomy needle claims at the PTAB, asserting obviousness under 35 U.S.C. § 103. The Petitioner argues that combining multiple prior art references—including Racz, Fitz, and Lee—would have motivated a Person of Ordinary Skill in the Art to create the claimed device.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical filed a Petition challenging Stratus Medical's RF neurotomy needle patent ('782 Patent). The central argument is that the claimed device is obvious because it merely combines conventional features from prior art references like Racz, Fitz, and Lee. This challenges 27 claims related to advanced medical ablation technology.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute IPR proceedings against Stratus Medical's patent, demonstrating a reasonable likelihood of success on obviousness grounds. The Board found sufficient evidence that the claimed RF neurotomy features could be achieved by combining existing prior art references.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found all 29 challenged claims unpatentable by a preponderance of evidence. The Board rejected the Patent Owner's argument that the invention was limited to RF neurotomy, adopting Petitioner's broader view of 'thermal ablation systems.'
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.